Skip to content

Pharminent

cropped-ChatGPT-Image-Jun-22-2026-05_46_48-PM.png
Primary Menu
  • Home
  • Signal News
  • Biopharma Brief
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact
Light/Dark Button
Brief
  • Home
  • Market Access
  • Where Gross-to-net Pressure Actually Lives After Launch
  • Market Access

Where Gross-to-net Pressure Actually Lives After Launch

Drug Channels

Today's guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Read full story

pharminent May 1, 2026 (Last updated: May 1, 2026)

Drug Channels

Today’s guest post comes from Cindy Baksh, Chief Product Officer at ConnectiveRx.

Read full story

Sign up to receive free daily digest

Check your inbox or spam folder to confirm your subscription.

Post navigation

Previous: Two biotechs raise a combined $556M in latest spurt of IPOs
Next: BMS brings the buzz around late-stage readouts amid a so-so Q1

Related Stories

  • Market Access

pharminent June 12, 2026
  • Market Access

Aquipta recommended by NICE for acute migraine treatment

pharminent June 10, 2026
  • Market Access

AbbVie’s migraine drug cleared for migraine attacks on NHS

pharminent June 10, 2026

You May Have Missed

  • News

pharminent June 22, 2026
sample_feature_2026-06-22
  • News

AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet

pharminent June 22, 2026
  • M&A / Deals

AbbVie climbs post-Allergan M&A peak with Apogee buy

pharminent June 22, 2026
  • M&A / Deals

Lilly bets up to $800M for BioArctic’s brain delivery tech

pharminent June 22, 2026
© 2026 All rights reserved. | ReviewNews by AF themes.